Beth Hecht Net Worth & Insider Trades
Beth Hecht - See Remarks, Xeris Biopharma Holdings, Inc
What is Beth Hecht's Net Worth?
The current estimated net worth of Xeris Biopharma Holdings, Inc's See Remarks, Beth Hecht, is estimated to be about $562.49K . Beth Hecht owns about 57,083 units of Xeris Biopharma Holdings, Inc common stock. In the last 4 years at Xeris Biopharma Holdings, Inc, Beth Hecht has sold an estimated value of $0 worth.
What is Beth Hecht's Past Insider Trading?
Beth Hecht's largest purchase order was 2,500 units , worth over $25K on February 22, 2019. In total, Beth Hecht has made about 14 transactions over 4 years of their time at Xeris Biopharma Holdings, Inc. Beth Hecht usually trades in February, with the busiest year in 2020. The most recent transaction was a purchase order of 4,000 units , worth over $7.88K on March 16, 2020.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Beth Hecht
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |
InsideArbitrage
What was Beth Hecht's Salary in 2020?
As See Remarks of Xeris Biopharma Holdings, Inc, Beth Hecht has a total base salary of $392,852 . Beth Hecht received compensation valued at about $1,244,394 in 2020 after becoming See Remarks. The vast majority of their compensation came in the form of stock awards of $286,650 , option awards of $369,450 , other earnings, plans or compensations of $189,808 , and other compensation of $5,634 .
What is Beth Hecht's' Mailing Address?
- Mailing address is C/o Neos Therapeutics, Inc. 2940 N. Highway 360 Grand Prairie TX 75050 TX
Xeris Biopharma Holdings, Inc Executive Compensation
Name |
Year
|
Salary
|
Stock Awards
|
Option Awards
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
---|---|---|---|---|---|---|---|
Paul Edick, | 2020 | $626,977 | $1,178,450 | - | $453,222 | $5,700 | $2,264,349 |
Paul Edick, | 2019 | $598,277 | $1,735,000 | $1,598,580 | $370,181 | $5,600 | $4,307,638 |
John Shannon, | 2020 | $473,658 | $414,050 | $246,300 | $300,000 | $2,420 | $1,436,428 |
John Shannon, | 2019 | $444,479 | - | $639,432 | $178,500 | $5,171 | $1,267,582 |
Beth Hecht, | 2020 | $392,852 | $286,650 | $369,450 | $189,808 | $5,634 | $1,244,394 |
Beth Hecht, | 2019 | $364,417 | - | $259,769 | $145,782 | $5,600 | $775,568 |
No matching records found |
Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630221000036/a2021proxystatement.htm
What are Xeris Biopharma Holdings, Inc's Past Insider Trades?
Xeris Biopharma Holdings, Inc's most recent insider trade came on August 9, 2023 by Paul Edick who bought 10,000 units worth $23.79K . In the last 5 years, insiders at Xeris Biopharma Holdings, Inc have sold an estimated value of $3.18M and bought an estimated value of $31.39M worth of shares. Insider trading is most common in June, with the busiest year in 2021. The most active traders at the company are Steven Prestrelski, Chief Scientific Officer, Paul Edick, See Remarks, and Patrick John Shannon Jr, See Remarks .
Xeris Biopharma Holdings, Inc. Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |